Skip to main content
Premium Trial:

Request an Annual Quote

NuProbe Augury

NuProbe has launched an early-access program for its "Augury" platform, an automated design product for customized liquid biopsy NGS panels. Based on proprietary sequence-design algorithms, Augury procedurally generates NGS panels for cell-free DNA analysis, covering the entire coding regions of between one and 30 genes of interest. 

According to the company, these panels typically detect mutations down to 0.2 percent variant allele frequency, and copy number variations down to 4 percent tumor fraction, using 10 to 20 ng of cell-free DNA input. Users can choose to build panels that either cover the full coding regions of the genes of interest, or select hotspot loci. NuProbe expects typical panels to be designed within two days and analytically validated within 12 weeks.

The Scan

Boosters Chasing Variants

The New York Times reports that an FDA advisory panel is to weigh updated booster vaccines for COVID-19.

Not Yet

The World Health Organization says monkeypox is not yet a global emergency, the Washington Post reports.

More Proposed for Federal Research

Science reports that US House of Representatives panels are seeking to increase federal research funding.

PLOS Papers on Breast Cancer Metastasis, Left-Sided Cardiac Defects, SARS-CoV-2 Monitoring

In PLOS this week: link between breast cancer metastasis and CLIC4, sequencing analysis of left-sided cardiac defects, and more.